Journal of Clinical Lipidology

Article	Citations
Comparison of virtual vs face-to-face medical nutrition therapy in patients with hyperlipidemia	244
Hypercoagulability or coronary artery disease? Polygenic risk score unveils the mystery	154
Effective treatment of statin- and ezetimibe-resistant hyperlipidemia in a patient with active membranous nephrotic syndrome using a PCSK9 inhibitor	111
Assessment of health disparities in secondary ASCVD risk prevention in the elderly population in Greece	95
Lipoprotein(a) concentrations across a global cross-sectional registry	93
Disparities in statin use among individuals with and without cancer history across atherosclerotic cardiovascular disease risk categories	86
Genetic mutations and associated phenotypes in familial hypercholesterolemia: A biobank study	81
Care of youth with lipid disorders: A brief provider survey	74
†Role of DNA methylation on 15-Lipoxygenase-1 gene expression in Osteoarthritis	71
Mesenchymal Stromal Cell (MSC) Therapy Improve Nonalcoholic Fatty Liver Disease (NAFLD) in Long Term high Fat Diet (HFD) Induced Obesity (DIO) Mouse	66
Lower Activity of Cholesteryl Ester Transfer protein (CETP) and the Risk of Dementia: A Mendelian Randomization Analysis	66
The Effect of Estrogen and Testosterone on Cholesterol Crystallization	56
News from NLA	51
Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics - Implications for Precision Medicine	51
From the Editors: New insights into lipid disorders in children and adolescents as well as cardiovascular benefits of pharmacotherapy for weight loss	45
Prevalence of Lipoprotein(a) Measurements in Patients with or at Risk of Cardiovascular Disease	43
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes	43
Socioeconomic Disparities in Dyslipidemia and Associated Complications: From the Latest National Database	43
The impact of genetic testing on physician practice in specialized cardiovascular clinics	42
Niacin (Niacin) and clinical utility, don't be misled by recent niacin (Niacin) metabolite report	42
Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An Expert Clinical Consensus from the National Lipid Association and the Americ	40
Lipoprotein(a) levels in children with homozygous familial hypercholesterolaemia: A cross-sectional study	38
Exciting new developments in clinical lipidology: Updates from the Food and Drug Administration and the American Heart Association	37
Healthcare utilization and expenditures among adults with severe hypertriglyceridemia in US clinical practice	36
Impact of providing genetics-based future cardiovascular risk on LDL-C in patients with familial hypercholesterolemia	34

Inflammation and cardiometabolic disease in South Asians: The fire and fire tenders	34
Association of Lipoprotein(a) with peri-coronary inflammation in persons with and without HIV infection	34
Achievement of low-density lipoprotein cholesterol thresholds in very high-risk atherosclerotic cardiovascular disease	33
Predictive value of lipoprotein(a) in patients undergoing percutaneous coronary intervention with drug-eluting stent: A meta-analysis	31
Lipoprotein lipase DNA methylation in the adipose tissue of patients with persistent chylomicronemia	31
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association	31
Lomitapide in Pediatric Patients with Homozygous Familial Hypercholesterolemia – Analysis of Secondary and Safety Endpoints from the APH-19 Study	30
*Real-World Experience with Inclisiran at a Large Academic Lipid Clinic	28
From the Editors: Familial hypercholesterolemia: Still underdiagnosed and undertreated	27
News from the NLA	25
From the Editors: Update on Diagnosis and Treatment of Familial Hypercholesterolemia	24
Triglyceride-rich lipoprotein sphingolipids are altered in primary hypertension: A pilot case-control study	24
Early-Pregnancy Remnant Cholesterol as a Modifiable Risk Factor for Gestational Diabetes Mellitus	23
Association of sleep duration and quality with small dense low-density lipoprotein cholesterol	22
Efficacy for LDL-C–lowering and safety of pemafibrate extended-release formulation in patients with statin-intolerant hypercholesterolemia: A phase 3 multicenter, randomized, double-blind, placebo-con	22
Characterization of Inclisiran Use in Real World: Prescription Data from Germany	22
Circumferential periorbital xanthelasma in Leonardo da Vinci’s Head of a Young Woman (1475-1480)	21
Severe hypertriglyceridemia induced by everolimus in a lung transplant patient: Case report	21
Country-specific prevalence and clinical relevance of elevated Lp(a) as a risk enhancer in 2 Greek cohorts	21
Dyslipidemia among elderly patients with hyperuricemia and gout: Insights from the National Inpatient Sample	20
Elevated lipoprotein(a) levels attenuate LDL-C lowering in acute coronary syndrome patients treated with triple combination lipid-lowering therapy	20
Cardiovascular and pregnancy outcomes in women with hyperlipidemia with and without hypertension: A real-world evidence study	20
Increased risk of ASCVD in women with PCOS is only partially mediated by incident metabolic comorbidities	20
Acute pancreatitis events among patients with severe hypertriglyceridemia: A retrospective study	18
Promoting lipoprotein(a) awareness and testing for risk identification through outreach and teaching (PATRIOT-QI)	18
Table of Contents	17
Unique Case of Management of Severe Hypertriglyceridemia Secondary to Familial Chylomicronemia Syndrome	17
⁎ Incidental Coronary Calcium on Non-Gated CT Scans of the Chest: A Stepwise Approach to Addressing Underreporting and Implementing Deep Learning	17
The Healthy Eating Assessment Tool (HEAT): A Aimplified 10-Point Assessment of CHILD-2 Dietary Compliance for Children with Dyslipidemia	16
Effects of pemafibrate on liver fibrosis in patients with MASLD and hypertriglyceridemia: A 2-year retrospective observational study using MR elastography	15
The Relationship of Alcohol Consumption and HDL Metabolism in the Multiethnic Dallas Heart Study	15
Improvement of severe hypertriglyceridemia in atypical subtype 4 partial lipodystrophy with volanesorsen	15
Lipid profile and risk factors for neoatherosclerosis after drug-eluting stent implantation in acute coronary syndrome	15
A variant in the fibronectin (FN1) gene, rs1250229-T, is associated with decreased risk of coronary artery disease in familial hypercholesterolaemia	15
Health outcomes and survival among patients with severe hypertriglyceridemia after acute pancreatitis	15
Remnant cholesterol and kidney disease progression in type 2 diabetes: A retrospective cohort study	15
Possible explanations for the common clinical familial hypercholesterolemia phenotypes in the Faroe Islands	15
Disruption of HDL antioxidant properties in children and adolescents with obesity	15
A Machine-Learning Algorithm using Claims Data to Identify Patients with Homozygous Familial Hypercholesterolemia (HoFH)	14
Management of Atherogenic Dyslipidemia in a Patient with LDL Discordance	14
Editorial Board	14
†Safety and Efficacy of Bempedoic Acid in Patients with Hypertension	14
Marked Hypoleptinemia precedes Overt Fat Loss in Immune Checkpoint Inhibitor-induced Acquired Generalized Lipodystrophy	14
*An Unsolved Case: FH or Sitosterolemia?	14
Characteristics Associated with Inclisiran Initiation in Outpatient Physician Clinics	13
303 Incremental Benefit of Atherogenic Cholesterol Reduction with Obicetrapib Administered with Moderate-Intensity Statins	13
†Cardiovascular Trials Over the Last 15 years: Analysis of the Characteristics and Trends of ClinicalTrials.gov Listings from 2008 to 2022	13
From the editors: Upcoming treatments for familial chylomicronemia syndrome: Agents that inhibit production of apolipoprotein CIII	13
Clinical profile, genetic spectrum and therapy evaluation of 19 Chinese pediatric patients with lipoprotein lipase deficiency	13
Comparative cardiovascular outcomes of triple lipid-lowering therapy versus double therapy in patients with atherosclerotic cardiovascular disease	13

Impact of baseline demographics on lipid profile in patients with ACS: Unmasking hidden drivers	13
Evaluating the underutilization of lipid-lowering therapy in Asian patients – A high-risk population	13
Tailored Therapeutic Strategies for the Management of Chylomicronemia Syndrome	13
Genetic Testing Results in a Preventative Cardiology and Inherited Lipid Disorders Clinic	12
Corrigendum to “Association between the cardiometabolic index and mortality risk in US adults: Data from the National Health and Nutrition Examination Survey (NHANES) 1999-2018” [Journal of Clinical L	12
Lipoprotein(a) and TAVR outcomes: Methodological challenges and clinical implications	12
Overcoming the real and imagined barriers to cholesterol screening in pediatrics	12
Novel APOB variant causes familial hypercholesterolemia in multiple unrelated families	12
Comprehensive assessment of the combined impact of dyslipidemia and inflammation on chronic kidney disease development: A prospective cohort study	12
The Family Heart Foundation™ Flag, Identify, Network, Deliver—Familial Hypercholesterolemia (FIND-FH™) Program and Collaborative Learning Network (CL	12
Variation in lipoprotein(a) response to potent lipid lowering: The role of apolipoprotein (a) isoform size	12
Serum mature and furin-cleaved proprotein convertase subtilisin/kexin type 9 levels and their association with cardiovascular events in statin-treated patients with cardiovascular disease	12
Fatty acid analysis in serum of patients with elevated lipoprotein(a) and cardiovascular disease undergoing lipoprotein apheresis	11
Long-term efficacy and safety of lomitapide in patients with familial chylomicronemia syndrome: Data from an expanded access program	11
Familial hypercholesterolemia concealed by a protein-truncating variant of PCSK9	11
Implementation strategies to optimize the use of nonstatin add-on lipid-lowering therapies in individuals with dyslipidemia: A systematic review	11
Treatment Patterns Among Early Inclisiran vs Anti–PCSK9 mAbs Users: A Retrospective Analysis of US Claims Databases	11
Extreme lipoprotein(a) is a cardiovascular risk equivalent in heterozygous familial hypercholesterolemia	11
Safety and effectiveness of evinacumab in an infant with homozygous familial hypercholesterolemia: A new renaissance for the very young?	11
Genetic association analyses highlight apolipoprotein B as a determinant of chronic kidney disease in patients with type 2 diabetes	11
Carotenoids in familial hypobetalipoproteinemia disorders: Malabsorption in Caco2 cell models and severe deficiency in patients	11
Response to the Letter Regarding “Beyond Lipid Lowering: Effects of PCSK9 Inhibition on Inflammation and HDL Function”	11
Association of cumulative low-density lipoprotein cholesterol exposure with vascular function	11
Enzyme replacement therapy in cholesteryl ester storage disease: A case report on lysosomal acid lipase deficiency management	11
The 2025 AACE Dyslipidemia Guidelines – Cost concerns over evidence and missing the target?	11
The causal association between lipid-lowering strategies and risk of intracranial aneurysms: A drug-target Mendelian randomization study	11
†Utility of AI-QCPA: Results of the Decisions for Treating Coronary Disease are Changed in Patients Evaluated with Quantified Plaque Analysis	10
Accelerated Atherosclerosis in a Patient With Multifactorial Chylomicronemia Syndrome (MCS), Elevated Lp(a), APOE2/4 Genotype and Diabetes Mellitus.	10
^Polygenic risk score for coronary artery disease predicts atherosclerotic cardiovascular disease in familial hypercholesterolemia	10
Multidisciplinary Management of Lipoprotein X-Induced Hyperlipidemia Secondary to Drug-Induced Liver Injury	10
Enhancing lipoprotein(a) association studies: A complementary approach to principal component analysis	10
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice	10
Community pharmacist impact of addressing statin use in patients with diabetes	10
Is Tangier disease a rare cause of premature ovarian insufficiency?: A case report	10
Habitual fish oil supplementation, genetic susceptibility of kidney stones and the risk of new-onset kidney stones	9
Time to benefit of intensive lipid lowering therapy in individuals with cardiovascular disease	9
Why Are Patients Presenting with STEMI Already on Statin Not Treated with Additional Aggressive Lipid-lowering Agents?	9
Functional profiling of LDLR variants: Important evidence for variant classification	9
Clinical impact of ≥50% reduction of low density lipoprotein cholesterol following lipid lowering therapy on cardiovascular outcomes in patients with acute coronary syndrome	9
Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America	9
An Indian adapted Mediterranean diet: A feasibility study	9
Elevated Levels of Lp(a) are Associated with Circulating Levels of PCSK9 and Coronary Atherosclerosis as Detected by Cardiac Computed Tomography Angiography	9
ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk	9
GPIHBP1 autoantibody is an independent risk factor for the recurrence of hypertriglyceridemia-induced acute pancreatitis	9
Concordance between LDL-C estimated by various formulas and directly measured LDL-C	9
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Pre	9
Effects of evinacumab on high-density lipoprotein function in patients with homozygous familial hypercholesterolemia	9
Sex differences in the associations of HDL particle concentration and cholesterol efflux capacity with incident coronary artery disease in type 1 diabetes: The RETRO HDLc cohort study	9
Hourly 4-minute walking breaks from sitting following aerobic exercise reduce postprandial non-HDL cholesterol in healthy young adults: A randomized crossover trial	9
Impact of small dense low-density lipoprotein cholesterol and triglyceride-rich lipoproteins on plaque rupture with ST-segment elevation myocardial infarction	9
Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials	8
Evaluation of plasma phytosterols in sitosterolemia, their kindreds and hyperlipidemia subjects	8
Lipoprotein(a) screening for cardiac allograft vasculopathy among heart transplant recipients	8
Successful lipid-lowering in statin and PCSK9i intolerant patient with mixed hyperlipidemia: A case study of inclisiran as a therapeutic option.	8
Effect of pharmacologic anti-atherosclerotic therapy on carotid intraplaque neovascularization: A systematic review	8
Metabolic syndrome predicts cardiovascular risk and mortality in familial hypercholesterolemia	8
Differences in Clinical outcomes between Non-Obese Hispanic and Asian populations Who have Hyperlipidemia	8
Fellow Quality Improvement Project: Identification of High Risk CAD Patients and Referral to Newly Established Lipid Clinic, What are the Clinical Implications?	8
Physician-reported reasons for not intensifying lipid-lowering therapy in patients with recent myocardial infarction	8
Table of Contents	8
† Safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia	8
Bempedoic acid vs ezetimibe added to statin therapy: Cardiovascular outcomes in the real-world—The BEYOND-REAL Study	8
Attrition of adipose: Type 2 familial partial lipodystrophy manifesting in severe premature CAD	8
Modifications on lipid profile and high-density lipoprotein function related to treatment with tofacitinib in female patients with rheumatoid arthritis: Impact of previous therapy with biological agen	8
Treatment dilemmas faced by women of reproductive age with familial hypercholesterolemia: Case report	8
A novel homozygous nonsense variant of LMF1 in pregnancy-induced hypertriglyceridemia with acute pancreatitis	8
Differences in Clinical Outcomes between Non-Obese African American and Asian Populations Who have Hyperlipidemia	7
Assessment of lipid-lowering therapies in high-risk patients with inflammatory joint diseases—Insights from a preventive cardio-rheuma clinic	7
Evaluation of apolipoprotein A5 variants: A cohort of patients with severe hypertriglyceridemia from Turkiye	7
Lipoprotein(a) at the crossroads of inflammation and atherosclerosis in rheumatoid arthritis: A narrative review	7
Hyperlipidemia and risk for preclampsia	7
Association between very high HDL-C levels and mortality: A systematic review and meta-analysis	7
Validation of physical examinations of tendon xanthomas and changes in the cutoff values of Achilles tendon thickness on radiography in the clinical criteria of heterozygous familial hypercholesterole	7
Elevated Serum Small Dense Low Density Lipoprotein Cholesterol and Lipoprotein(a) Levels in Preeclampsia	7
Does apolipoprotein B matter in the care of familial hypercholesterolemia?	7
CAC Scoring as an Index for Subclinical Carotid Atherosclerosis	7
Associations of lipid-lowering drugs with cardiovascular-kidney-metabolic syndrome: A drug-target Mendelian randomization study	7
Heterogeneous nature of severe hypertriglyceridemia in childhood	7
† Cholesterol treatment trends from 2014 - 2023 in 3 Million US individuals with ASCVD: a retrospective cohort analysis using the Family Heart DatabaseTM	6
Association of inclisiran initiation on oral antilipemic therapy discontinuation rates	6

Lipoprotein(a): Mirroring Familial Hypercholesterolemia	6
In memoriam: A tribute to Dr Scott M. Grundy	6
Long-term monitoring of LPL gene replacement therapy: A lexicon of lessons for gene editing or oligonucleotide-based lipid lowering treatments	6
No benefit of vitamin D supplementation on muscle function and health-related quality of life in primary cardiovascular prevention patients with statin-associated muscle symptoms: A randomized control	6
*Sitosterolemia due to a new combination of ABCG8 variants presenting as hemolytic anemia and thrombocytopenia: A case report	6
†Food Compass Score is Inversely Related to Inflammatory Markers and Cardiovascular Disease Incidence: Results from the ATTICA Cohort Study (2002-2022)	6
From the editor: Lipidology resurgent as the pandemic wanes	6
Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial	6
Obicetrapib Lowers LDL-C in Patients Taking High Intensity Statins - Results from the ROSE Clinical Trial	6
Equitable Access to Screening and Lipid-Lowering Therapies in a Large Academic Center after Educational Interventions	6
Association between apolipoprotein B and obesity: A cross-sectional analysis of NHANES data	6
Cardiovascular disease and cholesterol lowering therapy in women and men with molecularly defined heterozygous familial hypercholesterolemia from Brazil	6
Sex differences in the presentation, treatment and outcomes of patients with homozygous familial hypercholesterolemia	6
Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors	6
Concerns regarding NMR lipoprotein analyses performed on the Nightingale heath platform – Focus on LDL subclasses	6
Pancreatitis polygenic risk score is associated with acute pancreatitis in multifactorial chylomicronemia syndrome	5
Utilizing gamification to educate internal medicine residents on managing lipids in patients with inflammatory conditions	5
Sex differences in inflammatory biomarkers during long-term evolocumab therapy	5
Obicetrapib and its impact on lipid parameters: A comprehensive meta-analysis of the latest evidence	5
Triglyceride-glucose index and triglyceride-glucose index-related markers for identifying metabolic syndrome in Saudi Arabia	5
The Food Compass Score is Negatively Related to the Activity of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in Healthy Adults.	5
† Higher Cardiovascular Event Rates for High-Risk Americans Who Did Not Meet 2018 Multidisciplinary Guideline on the Management of Blood Cholesterol Thresholds	5
^Sex Disparities in the Treatment and Outcomes of Familial Hypercholesterolemia	5
Genomic study of maternal lipid traits in early pregnancy concurs with four known adult lipid loci	5
Dedicated training in obesity management: A pathway to better physician practice	5
Disparities in access to pharmacotherapies for weight loss and cardiovascular prevention	5
+Racial Inequities in Coronary Artery Calcium Screening and Follow-up	5
High lipoprotein(a) and stroke: Association with large artery and intracranial atherosclerosis—A retrospective study	5
From the Editors: New 2026 guideline for management of dyslipidemia	5
Premature coronary artery disease in the absence of traditional risk factors - a hidden dilemma	5
Association of lipid-lowering drugs with gut microbiota: A Mendelian randomization study	5
From the editor: A compendium of lipidology progress	5
Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States	5
Neurodegeneration in familial chylomicronemia syndrome	5
Effect of Dexamethasone on Modulating Lp(a) Levels in COVID-19 Pneumonia	5
†Efficacy and Safety of Bempedoic Acid in Patients with Metabolic Syndrome	5
Comprehensive analysis of Chinese patients with non-LPL familial chylomicronemia syndrome: Genetic variants, dietary interventions, and clinical insights	5
†Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Deep and Durable TG Reductions in Patients With SHTG, SHASTA-2 Final Results	5
Impact of omega-3 supplementation on lipoprotein-associated phospholipase A2 mass and activity: A systematic review and meta-analysis of randomized controlled trials	5
Remnant cholesterol as a residual risk in atherosclerotic cardiovascular disease patients under statin-based lipid-lowering therapy: A post hoc analysis of the RACING trial	5
The analysis of the breakpoint of large rearrangements of LDLR gene in a Taiwanese cohort of patients with familial hypercholesterolemia	5
Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function	5
Is hypertriglyceridemia a reliable indicator of cholesterol-depleted Apo B particles?	5
What's next for lipoprotein(a)? A National Lipid Association report from an Expert Panel Discussion	5
Association of LDL-C between parents and younger offspring: A cross-sectional study using the Korea National Health and Nutrition Examination Survey	5
Treatment Target Achievement in Patients with Familial Hypercholesterolemia: A Real-World Descriptive Study	5
*A Novel ABCG8 Variant and Apo(A) Short Isoform Associated with Premature Atherosclerosis and Familial Hypercholesterolemia Phenocopy.	5
In memoriam, Avedis Khachadurian 1926 - Sept 22,2022	5
† Effect of plozasiran targeting APOC3 on lipoprotein particle number and size measured by NMR in patients with hypertriglyceridemia	5
Negative LDL-C levels with Detectable Apolipoprotein B: Surrogate Markers of Atherosclerotic Disease and Cardiac Event Risk	5
Remnant cholesterol and cardiovascular and all-cause mortality in Korean adults	5
One size doesn't fit all: A dose-dependent twist in PCSK9 monoclonal antibody therapy	4
Adherence to lipid monitoring and its impact on treatment intensification of LDL-C lowering therapies at an urban academic medical center	4
“Reconsidering uric acid to HDL ratio as a predictor of vascular calcification” author response to letter to the editor	4
Racial disparities in LDL-C control, ASCVD risk reclassification by statin use, coronary artery calcium scores, and the Pooled Cohort Equation	4
Detailed Family History of Premature Atherosclerotic Cardiovascular Disease to Guide Lipoprotein(a) Testing: The Multi-Ethnic Study of Atherosclerosis	4
Improving adherence with lipid-lowering agents	4
New directions in childhood obesity treatment – A path forward or wishful thinking?	4
Timing of PCSK9i Initiation and Its Relationship with Clinical Outcomes in US Patients with Prior Cardiovascular Events: A Claims Database Analysis	4
Association of lipoprotein(a) with peripheral artery disease and outcomes: A propensity-matched retrospective analysis	4
Successful pregnancy outcome in a woman with cholesteryl ester storage disease treated with enzyme replacement therapy	4
Prevalence, patterns, and geographical distribution of cardiometabolic multimorbidity and its association with unhealthy behaviors among Chinese adults: Evidence from the China National Nutrition Heal	4
Symptom and Comorbidity Burden in Familial Chylomicronemia Syndrome: Impact on Quality of Life	4
Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial” [Journal of Clinical Lipid	4
Race/ethnicity and socioeconomic status affect the assessment of lipoprotein(a) levels in clinical practice	4
Lipoprotein(a), metabolic profile and new-onset type 2 diabetes in patients with familial combined hyperlipidemia: A 9 year follow-up study	4
Predicting resilience in heterozygous familial hypercholesterolaemia: A cohort study of octogenarian patients	4
Impact of conducting a genetic study on the management of familial hypercholesterolemia	4
Effect of hormone replacement therapy on in-hospital outcomes of ischemic stroke in older women with dyslipidemia: A large-scale nationwide analysis	4
Positive association between apolipoprotein B and colorectal cancer risk: Findings from a 14-year follow-up cohort study and Mendelian randomization analyses	4
A Single-Dose, Randomized, Open-Label, Two-Period Crossover Bioequivalence Study in Healthy Adults Comparing Two Subcutaneous Formulations of Olezarsen: (Vial and Autoinjector) at Two Dose Levels	4
Oral semaglutide and reduction in major adverse cardiovascular events	4
CME Activity Highlights the Improvement in Clinician's Knowledge and Competence about Treatment Choices for LDL-C Lowering Post-MI	4
Severe Medication Induced Dyslipidemia in an Adult with Breast Cancer	4
Improving cholesterol management in high-risk primary prevention patients: An evidence-based case series	4
Discontinuation of lipid-modifying agents and failure to achieve target LDL cholesterol levels across cardiovascular risk groups	4
Lipedema is not obesity—A call for clinical clarity	4
Pharmacotherapy development and trends in lipidology: An expert discussion	4
Severe Hypertriglyceridemia as a Cause of Arterial Thrombosis with Peripheral Embolic Complications.	4
Unveiling Compound Heterozygous Familial Hypercholesterolemia	4
Kawasaki disease and familial hypercholesterolemia: Their potential synergistical impact on coronary arterial vascular health and viewpoints	4
Lipids management in patients with diabetes mellitus: Experience from a cohort study in Greece.	4
Attitudes and barriers to lipoprotein(a) testing: A survey of providers at the University of Pennsylvania Health System	4
Composition and distribution of lipoproteins after evolocumab in familial dysbetalipoproteinemia: A randomized controlled trial	4
Diagnosis and Management of Familial Dysbetalipoproteinemia in a Patient with Apo E2/E2 Genotype	4
Evaluation of Lp(a) for cardiovascular disease risk prediction in the veteran's health administration	4
Pegylated-Asparaginase Induced Severe Hypertriglyceridemia in an Adult with Acute B-cell Lymphoblastic Leukemia	4
Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table	4
A case of lipoprotein glomerulopathy due to the pathogenic APOE Las Vegas variant c.509C > A: p. (Ala170Asp)	4
Reframing lipoprotein(a): From physician knowledge gaps to a multidisciplinary translational gap	4
Pancreatitis in severe hypertriglyceridemia is a failure of temporal lipoprotein buffering: Not a problem of static lipid burden	4
Editorial Board	4
Assessing omega-3 fatty acids–critically weighing options and relevance	3
Long-term experience with lomitapide treatment in patients with homozygous familial hypercholesterolemia: Over 10 years of efficacy and safety data	3
Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3	3